Title: Her-2
First published: 1998
Description: Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer free. This is the biography of Her-2, Herceptin, the drug that provoked dramatic responses in Barbara and other women in the trials that offers promise for hundreds of thousands of women.
Subjects: HER-2 gene, Breast, Cancer, Trastuzumab, HER-2 protein, Immunotherapy, New York Times reviewed, Breast, cancer, Cancer, treatment, Cancer, immunotherapy, Monoclonal antibodies, Breast Neoplasms, Therapy, Therapeutic use, Borstkanker, Gentherapie, Drug therapy
LC classification: RC280.B8 B396 1998